Phase I, Phase I-II

A Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of LNS8801 in Patients With Advanced Cancer

Volunteers
Health Professionals

What is the purpose of this trial?

LNS-101 is a multi-center study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of LNS8801 in patients with advanced cancer. This Phase 1, first-in-human, open-label, multi-center study is designed to determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D). LNS8801 will be administered until disease progression or unacceptable toxicity.

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Ingrid Palma

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Jeffrey Ishizuka, MD, DPhil
Assistant Professor

Sub-Investigators

Last Updated
09/08/2023
Study HIC
#2000026326